Rapamycin Plus Vildagliptin to Recover ß Cell Function in Long Standing Type 1 Diabetes: A Double Blind Randomized Trial.

Like Comment
The aim of this study was to investigate whether treatment with rapamycin plus vildagliptin restores beta-cell function in patients with long-standing type 1 diabetes.A phase 2, single-center randomized, double-blind, placebo-controlled study was conducted in long-standing type 1 diabetes patients randomized (1:1:1) to 4 weeks rapamycin (Group 2), 4 weeks rapamycin plus 12 weeks vildagliptin (Group 3) or double placebo (Group 1). Primary outcome was the proportion of participants with a positive response to the Mixed Meal Tolerance Test (C-peptide at 90 min >0.2 nmol/L) at week 4 and 12. Secondary endpoints included insulin requirement, standard measures of glycemic control, hormonal and immunological profile.Fifty-five patients were randomized to Group 1 (n=18), Group 2 (n=19) or Group 3 (n=18). No patient in any group showed a positive C-peptide response and there was no significant difference at 4 and 12 weeks for the primary outcome. At four week insulin requirement decreased from 0.54 to 0.48 U/kg/day in Group 2 (p = 0.013), from 0.59 to 0.51 U/kg/day in Group 3 (p <0.001), while it did not change in Group 1. At 12 week HbA1c significantly decreased both in Group 2 [from 7.3% (56 mmol/mol) to 7% (53 mmol/mol); p= 0.045] and in Group 3 [from 7.2% (55.5 mmol/mol) to 6.9% (52 mmol/mol); p=0.001]. Rapamycin treatment was associated with a decrease in insulin antibody titer and changes in hormonal/immunological profile.Rapamycin reduced insulin requirement, but did not restore beta-cell function in patients with long-standing type 1 diabetes.

View the full article @ The Journal of clinical endocrinology and metabolism

Get PDF with LibKey


The wider, wiser view for healthcare professionals. ClinOwl signposts the latest clinical content from over 100 leading medical journals.
6584 Contributions
0 Following